Business
Directors Dealings / Market Share Purchases
Directors Dealings / Market Share Purchases.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9538J\n Oxford Biomedica PLC\n 29 April 2022\n \n \n \n \n \n \n \n \n \n \n Directors Dealings / Market Share Purchases\n \n \n \n \n \n \n Oxford, UK \n \n - 29 April 2022:\n Oxford Biomedica plc (\"Oxford Biomedica\" or \"the Group\") (LSE: OXB), a leading gene and cell therapy group, today announces\n \n that Catherine Moukheibir, a Non-Executive Director of the Company, has purchased shares in the Company. \n \n \n \n \n \n As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based outside of the UK to reflect market levels of remuneration based for Non-Executive Directors not based in the UK, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.\n \n \n \n \n \n Catherine Moukheibir has purchased 2,467 ordinary shares of 50p each (\"Ordinary Shares\") in the Company on 29 April 2022 on the London Stock Exchange at a price of 570.9p under the terms of a market purchase agreement. Following this purchase Catherine Moukheibir holds 2,467 Ordinary Shares representing 0.002% of the Company.\n \n \n \n \n \n \n \n \n The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.\n \n \n \n \n \n 1.\n \n \n Details of the person discharging material responsibilities/person closely associated\n \n \n \n \n \n a.\n \n \n Name\n \n \n Catherine Moukheibir\n \n \n \n \n \n 2.\n \n \n Reason for the notification\n \n \n \n \n \n a.\n \n \n Position/status\n \n \n Non-Executive Director\n \n \n \n \n b.\n \n \n Initial notification /amendment\n \n \n Initial notification\n \n \n \n \n \n 3.\n \n \n Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor\n \n \n \n \n \n a.\n \n \n Name\n \n \n Oxford Biomedica plc\n \n \n \n \n \n b.\n \n \n Legal Entity Identifier\n \n...